crypto currency Top Reviews

1. Now the market has returned to the human nature stage of opening higher and going lower, opening lower and going higher. I've been watching more emotional outbursts and higher prices, but it happened that the market was calmed down by smashing the market, and everyone was more pessimistic. When I felt that the low price was going to plummet, the main institutions stood up and pulled up.If you choose the right direction, the rest is the problem of holding shares. If you don't find the right direction, you will increase your workload.

Domestic substitution and expanding domestic demand, in essence, is not the corresponding technology and big consumption? The direction has been given to everyone above, so you can just wait for the trend to make money.At this time, institutions will either choose some high dividends or some oversold industry leaders as a defense. Those who want to catch the daily limit and buy and sell in day trading are more likely to lose money.For retail investors, today is still more suitable for holding shares to rise. If you bought yesterday, you don't have to worry about it in the short term. As long as you follow the above-mentioned directions of technology, consumption and real estate, at least the policy is supportive, and it is not chasing high in the short term.

At this time, institutions will either choose some high dividends or some oversold industry leaders as a defense. Those who want to catch the daily limit and buy and sell in day trading are more likely to lose money.Today's A-share shrinkage is too obvious. Don't expect to get out of the anti-package, and it is not allowed to do so now. Institutions will definitely exert their strength when the market is calm. Today is the slow cow that meets the above requirements, but when the mood is calm, the quantity will also come down. How to understand it?The plates were those that opened higher yesterday, and they have been further repaired today. At the end of the year, don't always think about chasing the daily limit, low-level consumer medicine, and the industry's low valuation leader, holding it steadily in the cyclical direction.